What question did this study set out to answer?

Evaluate the effect of elexacaftor-tezacaftor-ivacaftor on lung transplant needs for cystic fibrosis.

March 14, 2026Open Access

The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France

Key Points

Evaluate the effect of elexacaftor-tezacaftor-ivacaftor on lung transplant needs for cystic fibrosis.
Reviewed transplant data for cystic fibrosis patients in France
Analyzed response to elexacaftor-tezacaftor-ivacaftor
Assessed indications for first-time and re-transplantation
ETI reduced need for first-time lung transplant but did not eliminate it
Indications persist for patients who respond poorly to ETI
Re-transplantation remains viable for select cases with chronic lung issues

Abstract

ETI has reduced, but not eliminated, the need for a first-time lung transplant in pwCF. Indications for a first-time lung transplant persist in a small subset of pwCF who respond to ETI and in those with nonresponsive CFTR genotypes. Re-transplant remains an option for selected transplant recipients with chronic lung allograft dysfunction.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper